Clinical Study

Alendronate as an Effective Treatment for Bone Loss and Vascular Calcification in Kidney Transplant Recipients

Masanori Okamoto, Shintaro Yamanaka, Wataru Yoshimoto, and Takashi Shigematsu

Division of Nephrology, Department of Internal Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama City, Wakayama 641-0012, Japan

Correspondence should be addressed to Masanori Okamoto; mokamoto@wakayama-med.ac.jp

Received 21 November 2013; Accepted 15 January 2014; Published 19 February 2014

Academic Editor: Bruce Kaplan

Copyright © 2014 Masanori Okamoto et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Kidney transplant recipients develop secondary osteoporosis induced by immunosuppressive medication, with a high risk of fracture, and abdominal aortic calcification (AC) is a known predictor of cardiovascular mortality. In this study of 12 stable kidney recipients, we estimated the preventive effect of bisphosphonate treatment on bone loss and progression of AC. We randomly divided the subjects into a treatment group with alendronate (group A: 5 subjects) and a control group (group C: 7 subjects). Group A patients received 35 mg/week of alendronate over 24 months, while group C patients were not administered with any bisphosphonates. Two major endpoints were established: (1) the time-dependent change in bone mineral density (BMD) estimated with DEXA and (2) progression of abdominal AC, calculated twice as an index (ACI) using computed tomography data. Over the 2-year study period, group A patients showed significantly increased BMD of 1.86 ± 0.85% (P = 0.015 versus baseline), and almost complete inhibition of ACI progression (38.2 ± 24.2% to 39.6 ± 24.3%), but group C patients showed a decrease in BMD decline with bone loss and progression of ACI (32.8 ± 25.0% to 37.8 ± 29.2%, P = 0.061). In conclusion, alendronate therapy was an effective treatment in kidney transplant recipients for secondary osteoporosis and vascular calcification as ectopic calcification. This clinical trial is registered with number JMA-IIA00155 of JMACCTCTR.

1. Introduction

Renal transplantation is the gold standard therapy for end-stage renal failure, but the subsequent bone loss is related to adverse effects of immunosuppressive drugs on bone remodeling and bone quality [1, 2]. Osteoporosis and fragility fractures are serious complications of renal transplantation [3], and the choice of immunosuppressive drug, malnutrition, adynamic bone disease, and secondary hyperparathyroidism are important factors in the development of posttransplant osteoporosis [4]. Mineral and bone disorders following kidney transplantation are common and characterized by loss of bone volume and mineralization abnormalities, often leading to low turnover bone disease [5]. The incidence of fractures in kidney transplant recipients is threefold higher than in dialysis patients [6–8]. Fracture rates and bone mineral density (BMD) are associated with secondary osteoporosis, although not as strongly as with primary osteoporosis. Glucocorticoids are potent skeletal toxins, with even small doses causing a significant decrease in bone mass and increased fracture rate in previously healthy bone [9], and calcineurin inhibitors are also linked to osteoporosis [10, 11]. Bisphosphonates can prevent bone loss and fractures in patients with postmenopausal osteoporosis [12] or glucocorticoid-associated osteoporosis [13].

Accumulating epidemiologic evidence suggests that osteoporosis coexists with cardiovascular disease [14–16]. Progression of aortic calcifications associated with faster bone loss [16, 17] and low BMD has been shown to predict cardiovascular events and cardiovascular mortality [18, 19]. In chronic kidney disease (CKD), observational studies have shown a strong inverse correlation between BMD and cardiovascular mortality, as well as vascular calcification [20, 21]. Moreover, calcium apatite, which forms the crystal component of bone, has been found to accumulate in calcified blood vessels of many patients with CKD, and...
calcified plaques also express several bone matrix proteins that stimulate vascular smooth muscle cells to differentiate into osteoblasts. These findings support an important interaction between bone disorders and calcification of soft tissues [22, 23].

In the early posttransplantation period, observational studies have shown progression of both coronary and aortic vascular calcifications in kidney recipients [24, 25], a finding that possibly is linked to accelerated bone loss over the same period. Because several studies have shown that bisphosphonates can directly inhibit medial vascular calcification independent of bone resorption [26–28], we examined the preventive effect of bisphosphonate therapy on bone loss and progression of aortic calcification in kidney transplant recipients.

2. Materials and Methods

We enrolled 12 patients (8 men and 4 women) with stable allograft function (defined by serum creatinine <2.0 mg/dL) for at least 1 year and conducted a prospective study. We randomly divided the subjects into two groups: a treatment group with alendronate 35 mg/week for 24 months (group A: 5 subjects) and a control group (group C: 7 subjects) not given any bisphosphonates.

Two major endpoints were established: (1) time-dependent change in BMD, estimated from dual-energy X-ray absorptiometry (DEXA) scans of the whole body, and (2) progression of abdominal aortic calcification assessed by twice calculating an index (ACI) using computed tomography data. All patients underwent measurement of serum calcium, phosphate, bone-specific alkaline phosphatase (BAP), vitamin D metabolites, N-terminal telopeptides of bone-specific type I collagen (NTx), and whole parathyroid hormone (wPTH) levels at baseline and at 12 and 24 months. Allograft function was evaluated by measuring estimated glomerular filtration rate (eGFR) based on serum creatinine.

2.1. Statistical Analysis. All analyses and calculations were performed with SPSS software, version 20 (SPSS, Chicago, IL, USA). All values are expressed as the mean ± standard error of the mean (SEM). Statistical analyses were performed using ANOVA and subsequent Tukey’s simultaneous multiple comparison test. Differences at \( P < 0.05 \) were considered statistically significant.

3. Results

Patients in group A did not experience any adverse events during the study period. There were no differences between groups in the clinical characteristics of the patients (Table 1).

There were no significant difference between groups in baseline serum calcium, phosphate, BAP, wPTH, 1,25-dihydroxycholecalciferol, and NTx levels, or eGFR (Table 2). There were also no significant temporal changes in serum calcium and phosphate levels, or eGFR, in either group immediately after the treatment period (Figures 1 and 2). Mean wPTH levels in group C showed a gradual increase during the study, but there were no significant between-group differences after the treatment period (Figure 1). Mean BAP levels in group C tend to be temporarily increased by 12 months, but decreased by 24 months, and there were no significant between-group differences after the treatment period. Serum 1,25-dihydroxycholecalciferol and NTx levels did not differ significantly between the treatment and control groups at 24 months (Figure 1). Over the 2-year study period, group A patients showed significantly increased BMD of 1.86 ± 0.85 (\( P = 0.015 \) versus baseline, Figure 3) and almost completely inhibition of progression in the ACI (38.2 ± 24.2% to 39.6 ± 24.3%, Figure 4). By contrast, group C patients showed a decline in BMD with bone loss (Figure 3) and progression of the ACI (32.8 ± 25.0% to 37.8 ± 29.2%, \( P = 0.061 \), Figure 4).

4. Discussion

Osteoporosis is a frequent complication of renal transplantation. Osteoporotic fractures reduce quality of life, increase morbidity and mortality, and increase healthcare costs [29]. The risk of the development and progression of vascular calcification after renal transplantation is well described in the literature. In this preliminary study, in which we compared the effect of alendronate therapy versus no

---

**Table 1: Baseline characteristics of patients.**

|                | Alendronate (\( n = 5 \)) | Control (\( n = 7 \)) | \( P \) value |
|----------------|---------------------------|-----------------------|--------------|
| Age (years)    | 52.8 ± 12.6               | 52.9 ± 7.3            | NS           |
| Male (%)       |                           | 80                    | 57           |
| Diabetes (%)   |                           | 40                    | 43           |
| HTN (%)        |                           | 80                    | 71           |
| Tac (%)        |                           | 80                    | 86           |
| Steroid (mg/day) |                           | 5                     | 4.7          |
| HD vintage (months) | 136.8 ± 142.3             | 711 ± 76.6            | NS           |
| Transplant vintage (months) | 59.6 ± 58.5             | 45.3 ± 42.3           | NS           |

HTN: hypertension; Tac: tacrolimus; NS: not significant.

**Table 2: Biochemical parameters and bone turnover markers at baseline.**

|                | Alendronate (\( n = 5 \)) | Control (\( n = 7 \)) | \( P \) value |
|----------------|---------------------------|-----------------------|--------------|
| Ca (mg/dL)    | 9.2 ± 0.4                 | 9.4 ± 0.5             | NS           |
| P (mg/dL)     | 3.5 ± 0.6                 | 3.3 ± 0.8             | NS           |
| wPTH (pg/mL)  | 28.5 ± 9.7                | 34.1 ± 12.4           | NS           |
| BAP (IU/L)    | 10.3 ± 2.3                | 13.0 ± 5.1            | NS           |
| 1, 25-(OH)2vitD | 40.3 ± 11.6           | 40.0 ± 17.6           | NS           |
| NTx           | 21.6 ± 12.3               | 20.0 ± 5.6            | NS           |
| eGFR (mL/min/1.73 m²) | 41.2 ± 9.9             | 35.1 ± 6.9            | NS           |

Ca: serum calcium; P: serum phosphate; wPTH: serum whole parathyroid hormone; BAP: serum bone-specific alkaline phosphatase; 1, 25-(OH)2vitD: serum 1, 25-dihydroxycholecalciferol; NTx: serum N-terminal telopeptides of bone-specific type I collagen; eGFR: estimated glomerular filtration rate; NS: not significant.
Renal transplantation is now a reasonably common and successful procedure. As the number of transplant recipients has grown, new challenges have arisen in the management of long-term complications of transplantation. Posttransplantation bone disease is such an important complication, because it occurs in a substantial proportion of patients. As a consequence, bone mass loss and bone fractures are common in kidney transplant patients and cause substantial morbidity. Among kidney recipients, the most important cause of osteoporosis is corticosteroid treatment.

Bisphosphonates inhibit resorption of bone by binding preferentially to skeletal sites where turnover rates are high, such as trabecular bone, and by directly suppressing the number and activity of osteoclasts. Also, they prevent the apoptosis of osteoblasts and osteocytes induced by glucocorticoids [30]. Bisphosphonates (risedronate, alendronate, ibandronate, zoledronic acid, and pamidronate) have been shown in numerous studies to prevent BMD loss after renal transplantation [31–37], but generally there has not been evidence of a reduction in the rate of fracture [32, 38]. The latter may reflect a lack of statistical power in the previous studies or may result from a true absence of an effect of bisphosphonates on improving bone strength after transplantation, despite attenuating BMD losses [39]. A significant concern with regard to bisphosphonate use after transplantation is the potential to prolong or induce adynamic bone. Few studies have included bone biopsy data, but in the study by Coco et al. [32], which demonstrated that pamidronate use was associated with preservation of BMD at both the femoral neck and lumbar spine, there was an increase in biopsy-proven adynamic bone disease after 6 months compared with placebo. It is unknown whether the increase in adynamic bone was detrimental or if the increase in BMD decreased the fracture risk. In the present study, we showed that alendronate therapy increased the BMD of the whole body in kidney transplant recipients.

Cardiovascular disease remains the leading cause of mortality in both patients on dialysis and those with a functioning renal transplant [40, 41]. Vascular calcification independently predicts cardiovascular disease, which is the major cause of
death in kidney transplant recipients. According to animal studies, bisphosphonates generally inhibit vascular calcification in a variety of models [42]. The first report of the effects of bisphosphonates on vascular calcification was in the 1970s, with experiments showing inhibition of soft tissue calcification in both animals and humans [43, 44]. Those data have been confirmed by more recent animal studies using several bisphosphonates at varying doses [45–47].

The exact mechanism by which bisphosphonates inhibit vascular calcification is unclear. It may be by inhibition of bone resorption, with the reduced efflux of calcium and phosphate limiting their availability for deposition in the vasculature [48]. A new study has shown that the osteoblastic differentiation of rat aortic vascular smooth muscle cells (VSMCs) is significantly reduced by the action of alendronate in a dose-dependent manner [49]. Another research indicates that alendronate inhibits artery calcification by upregulating osteopontin and osteoprotegerin expression in rat model [50]. Alternatively, bisphosphonates may have direct effects on the vessel wall and, similar to pyrophosphate, on crystal formation. There have been varying responses in clinical studies; studies performed in the general population have reported no difference in vascular calcification with bisphosphonate administration; however, according to the scarce clinical data from patients with CKD, these drugs can improve vascular calcification [27, 28, 51].

Bisphosphonate are potent inhibitors of bone turnover [39, 52] and, at least in CKD patients, low bone turnover (i.e., a dynamic bone disease) is associated with vascular calcification [31]. Previous work revealed a complex association between bisphosphonate use and cardiovascular calcification. According to a recent study, bisphosphonate use was associated with a high prevalence of cardiovascular calcification in woman aged <65 years [53].

Despite some data supporting a role for bisphosphonates in the management of vascular calcification, additional clinical studies of their use in kidney transplant recipients are required. In this study, we evaluated the preventive effect of bisphosphonate on bone loss and progression of aortic calcification. Although there is no well-established therapeutic approach to the management of bone and mineral disorders in renal transplant recipients, clinicians should continuously individualize therapy for their patients.

5. Conclusions

The present study demonstrated that the alendronate therapy is a desirable treatment for secondary osteoporosis with vascular calcification as ectopic calcification in kidney transplant recipients. However, the effect of bisphosphonates on fracture risk and patient mortality is still obscure and requires further large-scale study.

Conflict of Interests

None of the authors have any conflict of interests associated with this study.
Funding
This study was partially performed by funding of MSD K.K.

References
[1] K. Kodras and M. Haas, "Effect of kidney transplantation on bone," European Journal of Clinical Investigation, vol. 36, no. 2, pp. 63–75, 2006.
[2] C. R. Parker, A. J. Freomont, P. J. Blackwell, M. J. Grainge, and D. J. Hosking, "Cross-sectional analysis of renal transplantation osteoporosis," Journal of Bone and Mineral Research, vol. 14, no. 11, pp. 1943–1951, 1999.
[3] J.-P. Casez, K. Lippuner, F. F. Horber, A. Montandon, and P. Jaeger, "Changes in bone mineral density over 18 months following kidney transplantation: the respective roles of prednisone and parathyroid hormone," Nephrology Dialysis Transplantation, vol. 17, no. 4, pp. 1318–1326, 2002.
[4] E. Tatal, M. E. Uyar, T. Colak et al., "Low graft function and ongoing hyperparathyroidism are closely related to post-transplantation osteoporosis," Transplantation Proceedings, vol. 45, pp. 1562–1566, 2013.
[5] K. Kalantar-Zadeh, M. Z. Molnar, C. P. Kovesdy et al., "Management of mineral and bone disorder after kidney transplantation," Current Opinion in Nephrology and Hypertension, vol. 21, pp. 389–403, 2012.
[6] G. Coen, "Fracturing osteoporosis after kidney transplantation—what are the options?" Nephrology Dialysis Transplantation, vol. 11, no. 4, pp. 567–569, 1996.
[7] A. V. Cayco, J. Wyosmierski, C. Simpson et al., "Posttransplant bone disease: evidence for a high bone resorption state," Transplantation, vol. 70, no. 12, pp. 1722–1728, 2000.
[8] C. Mitterbauer and R. Oberbauer, "Bone disease after kidney transplantation," Transplant International, vol. 21, no. 7, pp. 615–624, 2008.
[9] T. P. van Staa, H. G. M. Leufkens, L. Abenhaim, B. Zhang, and C. Cooper, "Use of oral corticosteroids and risk of fractures," Journal of Bone and Mineral Research, vol. 15, no. 6, pp. 993–1000, 2000.
[10] A. Ugur, N. Guvener, I. Iklar, M. Turan, R. Erdal, and M. Haberal, "Osteoporosis after renal transplantation: single center experience," Transplantation, vol. 71, no. 5, pp. 645–649, 2001.
[11] R. Marcén, C. Caballero, J. Pascual et al., "Lumbar bone mineral density in renal transplant patients on neoral and tacrolimus: a four-year prospective study," Transplantation, vol. 81, no. 6, pp. 826–831, 2006.
[12] U. A. Liberman, S. R. Weiss, J. Bröll et al., "Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The alendronate phase III osteoporosis treatment study group," The New England Journal of Medicine, vol. 333, no. 22, pp. 1437–1443, 1995.
[13] J. D. Adachi, W. G. Benson, J. Brown et al., "Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis," The New England Journal of Medicine, vol. 337, no. 6, pp. 382–387, 1997.
[14] G. N. Farhat, I. A. Cauley, K. A. Matthews et al., "Volumetric BMD and vascular calcification in middle-aged women: the study of women's health across the nation," Journal of Bone and Mineral Research, vol. 21, no. 12, pp. 1839–1846, 2006.
[15] G. N. Farhat, E. S. Strotmeyer, A. B. Newman et al., "Volumetric and areal bone mineral density measures are associated with cardiovascular disease in older men and women: the health, aging, and body composition study," Calcified Tissue International, vol. 79, no. 2, pp. 102–111, 2006.
[16] E. Schulz, K. Afrai, X. Liu, J. Sayre, and V. Gilbane, "Aortic calcification and the risk of osteoporosis and fractures," Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 9, pp. 4246–4253, 2004.
[17] A. E. Hak, H. A. P. Pols, A. M. van Hemert, A. Hofman, and J. C. M. Witteman, "Progression of aortic calcification is associated with metacarpal bone loss during menopause: a population-based longitudinal study," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 8, pp. 1926–1931, 2000.
[18] L. B. Tanko, C. Christiansen, D. A. Cox et al., "Relationship between osteoporosis and cardiovascular disease in postmenopausal women," Journal of Bone and Mineral Research, vol. 20, pp. 1912–1920, 2005.
[19] W. S. Browner, D. G. Seeley, T. M. Vogt, and S. R. Cummings, "Non-trauma mortality in elderly women with low bone mineral density. Study of osteoporotic fractures research group," The Lancet, vol. 338, no. 8763, pp. 355–358, 1991.
[20] G. M. London, C. Marty, S. J. Marchais, A. P. Guerin, F. Metivier, and M.-C. de Vernejoul, "Arterial calcifications and bone histomorphometry in end-stage renal disease," Journal of the American Society of Nephrology, vol. 15, no. 7, pp. 1943–1951, 2004.
[21] J. Braun, M. Oldendorf, W. Moshage, R. Heidler, E. Zeitler, and F. C. Luft, "Electron beam computed tomography in the evaluation of cardiac calciumifications in chronic dialysis patients," The American Journal of Kidney Diseases, vol. 27, no. 3, pp. 394–401, 1996.
[22] S. M. Moe and N. X. Chen, "Vascular calcification in end stage renal disease," Clinical Calcium, vol. 12, pp. 1417–1422, 2002.
[23] C. Marchal, E. Coche, E. Goffin et al., "Progression of coronary artery calcification and thoracic aorta calcification in kidney transplant recipients," The American Journal of Kidney Diseases, vol. 59, no. 2, pp. 258–269, 2012.
[24] G. Lehmann, U. Ott, G. Stein, T. Steiner, and G. Wolf, "Renal osteodystrophy after successful renal transplantation: a histomorphometric analysis in 57 patients," Transplantation Proceedings, vol. 39, no. 10, pp. 3153–3158, 2007.
[25] E. Oschatz, T. Benesch, K. Kodras, U. Hoffmann, and M. Haas, "Changes of coronary calcification after kidney transplantation," The American Journal of Kidney Diseases, vol. 48, no. 2, pp. 307–313, 2006.
[26] K. A. Lomashvili, M.-C. Monier-Faugere, X. Wang, H. H. Malluche, and W. C. O’Neill, "Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure," Kidney International, vol. 75, no. 6, pp. 617–625, 2009.
[27] K. Nitta, T. Akiba, K. Suzuki et al., "Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis," The American Journal of Kidney Diseases, vol. 44, no. 4, pp. 680–688, 2004.
[28] T. Ariyoshi, K. Eishi, I. Sakamoto, S. Matsukuma, and T. Odate, "Effect of etidronate on arterial calcification in dialysis patients," Clinical Drug Investigation, vol. 26, no. 4, pp. 215–222, 2006.
[29] R. Mainra and G. Elder, "Review article: managing bone complications after kidney transplantation," Nephrology, vol. 14, no. 4, pp. 437–442, 2009.
and osteoblast apoptosis by bisphosphonates and calcitonin,” *Journal of Clinical Investigation*, vol. 104, no. 10, pp. 1363–1374, 1999.

[31] W. Groz, C. Nagel, D. Poeschel et al., “Effect of ibandronate on bone loss and renal function after kidney transplantation,” *Journal of the American Society of Nephrology*, vol. 12, no. 7, pp. 1530–1537, 2001.

[32] M. Coco, D. Glicklich, M. C. Faugere et al., “Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate,” *Journal of the American Society of Nephrology*, vol. 14, no. 10, pp. 2669–2676, 2003.

[33] J. R. Jeffery, W. D. Leslie, M. E. Karpinski, P. W. Nickerson, and D. N. Rush, “Prevalence and treatment of decreased bone density in renal transplant recipients: a randomized prospective trial of calcitriol versus alendronate,” *Transplantation*, vol. 76, no. 10, pp. 1498–1502, 2003.

[34] A. E. El-Agroudy, A. A. El-Husseini, M. El-Sayed, T. Mohnsen, and M. A. Ghoneim, “A prospective randomized study for prevention of postrenal transplantation bone loss,” *Kidney International*, vol. 67, no. 5, pp. 2039–2045, 2005.

[35] M. Haas, Z. Leko-Mohr, P. Roshger et al., “Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation,” *Kidney International*, vol. 63, no. 3, pp. I130–I136, 2003.

[36] J. V. Torregrosa, D. Fuster, S. Pedroso et al., “Weekly risedronate in kidney transplant patients with osteopenia,” *Transplant International*, vol. 20, no. 8, pp. 708–711, 2007.

[37] S. Abediazar and M. R. Nakhjavani, “Effect of alendronate on early bone loss of renal transplant recipients,” *Transplantation Proceedings*, vol. 43, no. 2, pp. 565–567, 2011.

[38] S. L.-S. Fan, M. K. Almond, E. Ball, K. Evans, and J. Cunningham, “Pamidronate therapy as prevention of bone loss following renal transplantation,” *Kidney International*, vol. 57, no. 2, pp. 684–690, 2000.

[39] J. Cunningham, “Bisphosphonates in the renal patient,” *Nephrology Dialysis Transplantation*, vol. 22, no. 6, pp. 1505–1507, 2007.

[40] R. N. Foley, P. S. Parfrey, and M. J. Sarnak, “Clinical epidemiology of cardiovascular disease in chronic renal disease,” *The American Journal of Kidney Diseases*, vol. 32, no. 5, supplement 3, pp. S112–S119, 1998.

[41] B. L. Kasiske, “Cardiovascular disease after renal transplantation,” *Seminars in Nephrology*, vol. 20, no. 2, pp. 176–187, 2000.

[42] N. D. Toussaint, G. J. Elder, and P. G. Kerr, “Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue,” *Clinical Journal of the American Society of Nephrology*, vol. 4, no. 1, pp. 221–233, 2009.

[43] H. A. Fleisch, R. G. Russell, S. Bisaz, R. C. Mühlbauer, and D. A. Williams, “The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo,” *European Journal of Clinical Investigation*, vol. 1, no. 1, pp. 12–18, 1970.

[44] R. G. Russell, R. Smith, M. C. Bishop, and D. A. Price, “Treatment of myositis ossificans progressiva with a diphosphonate,” *The Lancet*, vol. 1, no. 7740, pp. 10–11, 1972.

[45] E. Saito, H. Wachi, E. Sato, H. Sugitani, and Y. Seyama, “Treatment with vitamin K(2) combined with bisphosphonates synergistically inhibits calcification in cultured smooth muscle cells,” *Journal of Atherosclerosis and Thrombosis*, vol. 14, no. 6, pp. 317–324, 2007.

[46] P. A. Price, A. M. Roublick, and M. K. Williamson, “Artery calcification in uremic rats is increased by a low protein diet and prevented by treatment with ibandronate,” *Kidney International*, vol. 70, no. 9, pp. 1577–1583, 2006.

[47] K. Tamura, Y. Suzuki, M. Matsushita et al., “Prevention of aortic calcification by etidronate in the renal failure rat model,” *European Journal of Pharmacology*, vol. 558, no. 1–3, pp. 159–166, 2007.

[48] V. Persy, M. de Broe, and M. Ketteler, “Bisphosphonates prevent experimental vascular calcification: treat the bone to cure the vessels?” *Kidney International*, vol. 70, no. 9, pp. 1537–1538, 2006.

[49] S. Zhou, X. Fang, H. Xin et al., “Effect of alendronate on the Notch 1-RBP-Jk signaling pathway in the osteogenic differentiation and mineralization of vascular smooth muscle cells,” *Molecular Medicine Reports*, vol. 8, pp. 89–94, 2013.

[50] P. Jia, Y. Li, J. Wang, F. Zhang, K. Liu, and Z. Wang, “The effect of alendronate on the expression of osteopontin and osteoprotegerin in calcified aortic tissue of the rat,” *European Journal of Pharmacology*, vol. 682, no. 1–3, pp. 126–130, 2012.

[51] H. Hashiba, S. Aizawa, K. Tamura, T. Shigematsu, and H. Kogo, “Inhibitory effects of etidronate on the progression of vascular calcification in hemodialysis patients,” *Therapeutic Apheresis and Dialysis*, vol. 8, no. 3, pp. 241–247, 2004.

[52] S. M. Ott, “Long-term safety of bisphosphonates,” *Journal of Clinical Endocrinology and Metabolism*, vol. 90, no. 3, pp. 1897–1899, 2005.

[53] S. Elmariah, J. A. C. Delaney, K. D. O’Brien et al., “Bisphosphonate use and prevalence of valvular and vascular calcification in women: MESA (The Multi-Ethnic Study of Atherosclerosis),” *Journal of the American College of Cardiology*, vol. 56, no. 21, pp. 1752–1759, 2010.